ArticleQuantitative imaging in medicine and surgery2026
Prognostic value of lesion dissemination on
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent research suggests that the maximum distance between the two farthest tumor lesions (Dmax)-an indicator reflecting the degree of tumor dispersion-has prognostic value in certain lymphoma subtypes. This study aimed to explore the prognostic value of positron emission tomography/computed tomography (PET/CT) imaging features, particularly Dmax, in patients with advanced-stage nasal-type extranodal natural killer/T-cell lymphoma (ENKTL). Methods: A retrospective analysis was conducted. Using LIFEx software (version 7.3.0), imaging parameters, including the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and whole-body tumor Dmax, were measured. The optimal cut-off values for each parameter in predicting prognosis were determined using X-tile software. Cox regression analysis and the log-rank test were used to evaluate the prognostic value of each imaging parameter and clinical characteristic [gender, B symptoms, and Prognostic Index of Natural Killer cell lymphoma (PINK) score], and to identify independent prognostic factors. Results: A total of 104 patients with stage III/IV nasal-type ENKTL were enrolled in the study, which had a median follow-up duration of 98.6 months (interquartile range, 42.8-119.8). During follow-up, 70 patients experienced disease progression, and 56 died. Multivariate Cox regression analysis revealed that TLG was an independent risk factor for both progression-free survival (PFS) [hazard ratio (HR) =2.87, P=0.009] and overall survival (OS) (HR =2.66, P=0.044). After excluding TLG and MTV, which are difficult to obtain in routine clinical practice, Dmax remained an independent risk factor for PFS (HR =1.78, P=0.040) and OS (HR =1.83, P=0.044). Conclusions: When all the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.